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The te&nlqne of iotraeorcnary stentlng has achieved remark- 
able progress over the last fev years. Improved stent de@oyment 
tecboiqnes aad aptimizatIaa .1 pastpmmdaral maaagewat have 
draatatimIIy ~q~mved the safety af iatramnmag stent @ace- 
meat. At preseb ‘be kteidew af early vessel dasare after 
~~isevenlawerthanth3tafforsa~~a~~ 
most operators no lunger preserlbe aggresshe anbamgulatlon, 
bleeding wa~plieatlons are nneumnma. 
Steotiog bas become an eatremely e&dive treatment firr 
abrupt or threatened vessel dosure or far say sabaptimal aitgh 
graplde result durlag mnventional aagbpWy. Fortktmwe, 
large pmspective trials have demonstrated that its etlimq is 
Conventional balloon angioplasty, introduced >15 years ago, 
remains hampered by the persistence of two vexing problems: 
abrupt vessel closure during intervention and restenosis during 
follow-up. Despite improvement in operator skills and angio- 
plasty material and a better understanding of tbe underlying 
pathologic processes, the incidence of these complications has 
not decreased Pharmacologic intervention with direct-acting 
thrombin inhibitors or glyeoprotein IIb/IlIa receptor inhibi- 
tors, or both, may prevent the occurrence of these adverse 
events in certain subgroups of patients (l-3). However, bleed- 
ing problems are more frequent with some of these new drugs; 
therefore, further optimization of drug dosage is currently 
being investigated. Mechanical intervention with intracoronary 
stems was introduced for human clinical investigation in 1986 
(4). Their application should be considered as a second 
breakthrough technology in the geld of interventional cardiol- 
ogy. ‘Ibe purpose of this article is to provrde a concise overview 
on this subject, including suggestions on present indications 
and postprocedural management. 
Historical overview 
Histoy: port 1(19&i ta 1991). In 1984, Sigwart (Lamanne. 
Switzerland) and Puel (TWJ~OIEZ, Frame) first implanted, 
soperior to that of maveatiiaal aagiq&ty for primary resteaw 
sis prevmtiaa ia foal Iesiaas af same aatlve mrawy axtehs. 
OQObIg~tCUdtO~pdahtbo~C4IlldUSiiStO~*MVIS 
veh gdt Iesiaa~ 
Mechaiil support of the vessel wall explalas tlie sustalued 
zuI&gqwlKuestabserv~afterstmtbIg.Futurc~ 
mayludurktheuseefstentsasavelt&fork9mldrugd&eryluau 
atteqttofurtberrcdncetbebIcldmmof- 
(/Am Cull Gmfid 1996;27:757-6.5) 
-.- 
almost simultaneously, a stent in human coronary arteries (4). 
In 1987, Roubin (Birmingham, Alabama) (5) and Schatz (la 
Jolla, California) (6) and their coworkers performed the tirst 
stent implantation in the United States. Stems were initially 
implanted for the treatment of restenosis. Abrupt or threat- 
ened vessel closure after coronary angioplasty and treatment of 
saphenous vein graft oamwiogs were the nest indications. As 
always with a new technique, these initial experieruzs were 
reported in rather small observational trials or presented as 
uncontroikd data. Only 5 years after the initial implantation, 
the first two important studies, reporting registry results of 
observational multicenter hi& were published Serruys et al. 
(7) reported data on the Buropean Walktent (Schneider AG, 
Ziirich, Switzerland) and Schatz et al. (8) reported on use of 
the U. S. Pabnaz-S&ah (Johnson & Johnson) device. ‘lhese 
pioneer works pointed out severai problems: I) the ocaurence 
of subacute stem thrombosii which had art unacceptably high 
rate (20%) in the European stu$y, 2) tedinical hazards related 
to implantation of tbe d&ce with risk for stent loss or 
embolization (Pabnaz-Schatz stent) or wrong positioning 
(Wallstent), requiring implantation of multiple stents; 
3) bieedmg problems related to anticoagulation; and 4) dilIer- 
ent results accxxhng to the type of stent being used. At that 
time, it was eoneh&dthattheplaceofthistedmiifortbe 
treatment of obstructive comnary artery disease remained to 
he determined because of the high ineidenc: f eomptications. 
tIistay part 2 (1991 la 1993/l994). Nevertheless. a per- 
sistent belief of certain irtwzbgators in their technigue. better 
patient selectii and more adequate w m%nage- 
mentreducedtheixidemeoftheaforememioned~ 
tifnLsintheearly199b&andra&mmmdtrialscompariog 
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stenting with angiopiasty were initiated for primary and sec- 
ondary restenosis prevention and for the treatment of saphe- 
nous vein graft narrowings and sudden or threatened vessel 
closure during angiopiasty. These randomized trials were 
started much earlier than studies comparing angiopiasty and 
coronary artery bypass grafting. At present, only primary resten- 
osis prevention trials (Renestent I [Belgium/Netherlands] [9] 
and STRESS 1 [STent REStenosis Study] studies) [lo] have 
been completed and their data published. These data show 
favorable results for stenting, as will be discussed later. 
History: part 3 (E&3/1994 to ?). If the second part of stent 
history was characterized by a clear reduction of procedure- 
related complications and the completion of the first random- 
ized trials, the third part is characterized by better stent 
deployment techniques and abolition of oral anticoagulation 
after the intervention. Goldberg (11) and Coiombo (12) and 
co-workers demonstrated by means of intravascular ultrasound 
that, with conventional implantation techniques, stem deploy 
q ent was suboptimal in up to 87% of cases with incorrect 
apposition of the device with the vascular surface. They 
therefore suggested additional high pressure noncompliant 
balloon angiopiasty to fully expand the stent. Although a 
relation between stent underexpansion and subacute thrombo- 
sis has never been clearly documented, several investigators 
(13), using ultrasound, progressively diminished and finally 
stopped their postintervention anticoagulation regimen and 
observed, simultaneously, very low closure rates with combined 
aspirin-ticiopidine treatment. French investigators (14), in 
contrast, started a multicenter feasibility study on stenting 
without coumadin and without mandatory ultrasound in March 
1992. In December 1992, after adding ticiopidine (250 mg 
twice daily) to postprocedural treatment with aspirin and low 
molecular weight heparin, they observed (15,16) a reduction in 
the incidence of subacute thrombosis from 10.4% (145 pa- 
tients) to 1.3% (237 patients who received 1 month of subcu- 
taneous low molecular weight heparin), 1.7% (523 patients 
who received 2 weeks of heparin) and 1.8% (491 patients who 
received 1 week of heparin). At present, full antiplatelet 
therapy, without additional subcutaneous heparin and without 
ultrasound guidance but with “blind” high pressure angio- 
phrsty, has become routine clinical practice, mostly with the 
Pabnaz-Schatz and Giiturco-Roubin sterns but also in con- 
trolled safety trials such as the MUST (MUlticenter Stems 
Ticlopidme) study (using the “old” articulated Paimaz-Schatz 
stent). Today, elective and emergency stenting have become 
safe and feasible techniques in the hands of most interven- 
tionai cardiologists. This and a less steep learning curve (than 
that associated with other techniques such a, laser or atherec- 
tomy) explain the current success of coronary stems. Some 
investigators have introduced the current concept of endolu- 
mid vessel reconstruction which may imply greater than 
ordinary widening of coronary vessels by multiple or long stent 
impiantatio~ with the idea of improving long-term angio- 
graphic outcmne. 
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Current Stent Types 
Stents can be distinguished by their type of delivery system 
(self-expanding, balloon-expandable), their composition 
(metallic-stainless steel, cobalt-based alloy or tantalum; bio- 
degradable; polymeric) and their configuration (mesh struc- 
ture; slotted tube; coil). Although most stents are placed 
definitively in coronary vessels, this list should be completed 
with the temporary retrievable bailout stent (RX Flow Support 
Catheter, Advanced Cardiovascular Systems) (17). The foiiow- 
ing devices are currently used or still under clinical investiga- 
tion in humans: 
Wallstent (Schneider AG). This device, the first stent ever 
implanted in human coronary arteries, was used in Europe 
between 1986 and 1990. The self-expanding, wire mesh struc- 
ture covers -20% of the vascular surface, making it the 
densest stent. This high metallic density has been held respon- 
sible for the high early vessel closure rate (20%), as reported in 
the European Registry in 1991 (7), and the stent was therefore 
withdrawn from clinical investigation in 1990 (7,18). However, 
since 1994, the Wallstent has gained new interest, especially for 
treatment of vein graft lesions, in which stents may be placed 
without predilarion, a strategy that may diminish the risk for 
distal emboiization. Controlled multicenter trials, examining 
the safety and efficacy of this stent for restenotic native and 
new-onset vein graft lesions, will soon be initiated in Europe 
and the U.S. The investigators believe that with better depioy- 
ment techniques, the incidence of subacute closure will be 
much lower. 
Flexstoat (Gianturco-Roubin, Cook). Thii baiioon-expand- 
able, stainless steel, single-wire structure has been used since 
1987, initially only for the treatment of acute vessel closure 
during angiopiasty (19). The largest experience has been 
gained’ in the U. S., and observational trials (20) as well as risk 
factors analyses on adverse long-term outcome (21) have been 
published. Recently, favordbie results were reported in a 
small, randomized trial (22) of this stent for the treatment of 
suboptimal outcome after angiopiasty. These data will be 
discussed later. A new generation device with proximal and 
distal markers on the stent, capable of passing in large lumen 
GF guiding catheters, will soon be available. 
Palmax-Sebata stent (Johnson & Johnson International 
Systems). This balloon-expandable, stainless steel, slotted tube 
device, introduced in 1987, is the most studied and widely used 
stent in the world. The Renestent I and STRESS I trials were 
carried out with this stent, and ongoing trials of secondary 
restenosis prevention, bailout and graft stenting are being 
performed with this device. The first-generation Palmaz- 
Schatz stem comprised, in addition to the short stem, two 
tubes co~ected by a metallic bridge (articuiated stent). This 
weaker part of the stent has been held responsible for resten- 
osis by some investigators and the manufacturer has now 
released a spiral-like intersection that contains more metal but 
also makes it more rigid and less trackable (23). A heparin- 
coated form of this newly designed Pahnaz-Schatz stent wig be, 
used in future stent trials ‘A “biliary” type of Pahnaz-Schata 
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stem, with the same design but a slightly larger strut thickness, 
is available for implantation in large (>4.5 mm) saphenous 
vein grafts. 
W&or stent (Medtronic Interventional Vascular). This 
balloon-expandable, helicoid coil, radiopaque (tantalum) de- 
vice was the first of a new generation of stems released for 
clinical investigation in the early 1990s (24). It has mainly been 
used for restenotic lesions, bailout situations and vein graft 
disease. A fibrin-coated and a new sma!! wave design stent 
(with more surface coverage) will be under evaluation. 
Miem steot (Applied Vascular Engineering Inc., Rich- 
mond, Canada). This balloon-expandable, stainless steel stent 
is composed of different 4-mm segments of a continuous wire 
in zigzag design. Although this device has been widely used 
since 1994 in different settings, no large scale long-term 
angiographic follow-up data are available (25). The stent is 
characterized by excellent trackability and is available in 
diierent lengths. 
Cordis stem (Cordis). This balloon-expandable, tantalum, 
single-wire, helicoid stent is currently undergoing safety and 
efficacy evaluation in controlled studies (26). 
Multi Link stent (Advanced Cardiovascular Systems). This 
balloon-expandable, stainless steel device is characterized by 
multiple serial rings connected by several links. The stent is 
currently under evaluation. 
Modalities of Stent Placement 
Rok of intravascular t~ItmsomuL As mentioned preti- 
ously, this technique had imposed the use of additional high 
pressure, noncompliant balloon angioplasty in tubular and sow 
coil stems that enabled the concept of no anticcX@ation-tirll 
antiplatelet therapy (K&27). At present, controlled trials (such as 
the STRUT [Stent Treatment Region assessed by Ultmsound 
Tomography] study) are examining the impact of ultrasound on 
further decision-making (more additional angioplasty) after high 
pressure angioplasty (28). Current “blind high pressure” practice, 
which has resulted in very low subacute stent thrombosis rates, 
is probably as safe as ultrasound-guided stent placeacnt. 
Intravascular ultrasound, an essential research tool, does not 
seem imperative from this point of view. Completion of the 
STRUT (and similar) trials will elucidate whether ultrasound 
may improve the long-term efficacy of stenting by further 
reducing the incidence of restenosis. 
Role of tidopiiae onfl other sew aatiplatekt ageats. 
Ticlopidine, a thienopyridine derivative, has been shown to 
have a broad antiplatelet activity that is maximal after 3 days of 
treatment and ‘that persists for t 10 days after its withdrawal 
(29). Kiorically, this drug was used as premeditation for 
conventional angioplasty in patients with aspirin intoler- 
ance. Since the end of 1992, it has been used after stent 
implantation in a nonrandomized fashion with excellent 
results (15,16,?3). These observations have stimulated in- 
vestigators over the world to use this drug in combination 
with aspirin in most ongoing stem trials. One small random- 
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ized ultrasound-controlled single-center study by Blengino 
et al. (31) compared the utility of aspirin alone versus 
aspirin plus ticlopidine and found no more benefit with 
ticlopidine. Nevertheless, it seems useful, on the basis of 
larger French experiences, to prescribe ticlopidine 3 to 5 
days before elective stent placement. 
New antithrombotic drugs have been developed and used in 
patients with unstable syndromes undergoing conventional 
angioplasty (32). In view of the very low subacute stem 
thrombosis rates currendy being reported, the indication for 
these drugs after stenting is unclear. Future planned investi- 
gations may indicate categories of patients (large visible 
thrombus, acute myocardial inrarction) wbo will benefit from 
this treatment. 
Role of transradiol approach. In 1994, Kiemeneij et al. 
(33) first described the use of the radial artery as an entry site 
for elective placement of the Palmaz-Schatz stent. In the era of 
full anticoagulation and amiplatelet therapy, this alternative 
approach was very promising because bleeding problems were 
virtually absent. At present, wilh the overall reduction in 
bleeding compliitions, the tramradial technique seems less 
attractive, although it remains an elegant technique in the 
hancij of experienced operators. 
Technical aspects. Intracoronary stenting is technically 
more challenging than standard angioplasty. Stems are less 
trackable than modem angioplasty catheters and the stent 
delivery systems have a far larger profile. Incorrect judgment of 
the accessibility of the lesion is the major cause of deployment 
failure and stent embolization. Data are lacking, but one may 
assume that ‘5% of balloon-expandable s;ents are lost during 
implantation, mostly without sequelae as operators commonly 
retrieve in one movement guide wire, delivery system and 
guiding catheter in the descending aorta. Delivery systems with 
a stent-protective membrane, mostly used in the United States, 
appear safer but are less trackable. In general, if stent place- 
ment is intended, adequate backup (by an appropriate guiding 
catheter) and support (by use of extra support guide wires) is 
essential. 
Specific measures may facilitate the intervention. Correct 
positioning is easier with radlopaque stems (Wiktor. Cordis 
stent) or with these delimited by double markers (bfii0, new 
Gianturco-Roubin stem). Overall, the self-expandmg Wall- 
stent remains the most difhcult device to irDplR0t IXXectly 
beemw it lacks radiopacity and important shortening occurs 
during pullback of tbe protective membmne. 
~nqmalIy, tubular stents may cause side branch closure 
and prchr&it the application of percutaneous coronary inter- 
vention if ostial disease is “present in these side branches. 
Reported data (34.35) show that closure occurs rarely (<5%) 
and that its axwrence, which appears to imply no clinical 
sequelae, is mostly related to the presence of ostial disease of 
the branch. Therefore, coil stems should be implanted in the 
main artery if intervention in large (>2-mm) side bran&s is 
intended 
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T&k 1. Angiographic Success Rates After Conventiona: 
Coronary Angioplasty ~__- 
Success Rate it) 
study (ref no.) 
NHLBI 1977-1981 registry (36) 
l-vec;el disease 
2.vcsel disease 
3-vessel disease 
NHLBI 1985-1986 registry (36) 
I-vessel disease 
2-vessel disease 
3-vessel diiase 
M-HEART I (37) 
CAVEAT I (38) 
STRESS I(9) 
Angiopeptin (39) 
CAVEAT II (40) 
Qualitative 
Analysis 
(opmor) 
67.3 
55.2 
bO.1 
86.8 
78.9 
77.5 
96.4 
%.5 
91.4 
Quantitative 
Analysis 
(core laboratory) 
88.6 
81) 
92.6 
89.7 
79.0 
CAVEAT = Coronary Angioplasty Versus Directional Atherectomy: M- 
HEART = Multi-Hospital Eastern Atlantic Restenosis Trial; NHLBt = Na- 
tional Heart, Lung, and Blood Institute; ref = reference; STRESS = STent 
REStewsis SNdy. 
Limitations of Standard Balloon Angioglasty 
Angbgrapbic snceess and result. Angiographic success, 
detined as ~50% residual stenosis at the end of the interven- 
tion as assessed during off-line quantitative coronary angio- 
graphic analysis in the core laboratory, is not always present 
after an angioplasty that the operator has judged successful by 
visual assessment. Diierent success rates obtained after angio- 
plasty are listed in Table 1 (9,36-40). Over the course of time, 
these rates have tended to increase and the discrepancy 
between qualitative and quantitative angiographic analysis has 
decreased with growing experience, insight into the utility and 
accuracy of quantitative angiographic analysis and the perfor- 
mance of randomized trials. The latier have contributed to a 
better execution of the angioplasty procedure, as operators try 
to optimize their angiographic results by conventional means. 
Even though we “do better than before,” angioplasty will be 
unsuccessful in certain patients and suboptimal in others, 
perhaps causing persistence of angina in some patients or 
exposing others to a higher risk for restenosis. Different 
investigators (941-43) have shown that, independent of revas- 
ctdarization technique (angioplasty, directional atherectomy or 
stenting), an optimal angiographic result diminishes the risk 
for restenosis. 
S&optimal an&graphic results. A suboptimal angio- 
graphic result after coronary angioplasty is typically caused by 
acute elastic recoil, residual plaque burden and dissection. In 
the absence of heavily calcified plaque (for which lesion 
pretreatment with rotational atherectomy is a valuable option), 
intracoronary stent placement scaffolds the vessel wall and 
reduces its acute elastic recoil more than does angioplasty (47). 
This observation by Haude et al. (47) was confirmed in 
prospective studies such as the STRESS I trial, which demon- 
strated a higher immediate angiographic success rate (99.5% 
vs. 92.6%) and superior results (19 + 11% vs. 35 + 14% 
residual stenosis, mean 2 SD) with stenting (22). In a small 
randomized trial with 66 patients, Rodriguez et al. (22) showed 
that implantation of a Gianturco-Roubin stent after a subop 
timal result (residual stenosis ?40% 24 h after angioplasty) 
reduced the incidence of restenosis from 75.7% (if no further 
intervention was performed) to 21.2%. 
Although these data suggest that unplanned stenting should 
be performed for suboptimal results after angioplasty, no clear 
residual stenosis cutoff value has been proposed. It seems 
reasonable to advise stent implantation (Palmaz-Schatz or 
Gianturco-Roubin device) for a residual stenosis >25%, as this 
value was obtained in the Etenestent I and STRESS I trial after 
stenting. However, if a residual stenosis ~20% can be obtained 
with conventional angioplasty, there is no rationale for addi- 
tional stenting. 
Therefore, in view of this “the bigger, the better” theory, 
angioplasty may require new device assistance to increase 
angiographic success and to improve suboptimal angiographic 
results. 
Abrupt vessel elnsure. Vessel closure during angioplasty is 
unpredictable and still occurs with an unchanged nonnegligible 
incidence rate of 4.4% to 8.3% (44). The immediate and 
long-term outcome of patients who experience abrupt vessel 
closure during angioplasty are impaired. Despite combined 
reangioplasty, thrombolysis and urgent bypass grafting, a 6% 
Abrupt ur threateued vesse1 clusure duriug aogioplasty. 
After their initial description of the stenting technique in 1987 
(4), Sigwart et al. (48) reported a larger experience, restricted 
to bailout stenting, in 1988. Numerous observational trials with 
different stent types have since been reported (Table 2) 
(19,21,49-63). These studies have shcwn high technical suc- 
cess rates but striking differences in the incidence of adverse 
events. Etetween 1986 and 1993, the incidence of subacute stent 
thrombosis and related myocardial infarction did not decrease. 
Recently, the French multicenter study on stenting without 
coumadm (14) reported, in the subgroup with rescue stenting, 
a 3.4% closure rate with the addition of t&pi&me to the 
incidence of death and 33% incidence of myocardial infarction 
have been reported (44). 
Restenosis. Restenosis, treated repeatedly by conventional 
angioplasty, is safe and efficient but also more expensive than 
primary stenting or even grafting (45). Only their greater 
clinical need for repeat interjection, caused by reetenosis, 
discriminated patients treated with angioplasty from those who 
had undergone bypass grafting in all randomized trials that 
have compared these therapeutic options (46). Similar rates of 
death and myocardial infarction with these therapies provide 
an ethical basis for further transcatheter coronaty therapies. 
However, new device assistance seems mandatory to further 
improve the immediate safety and the long-term efficacy of 
angioplasty by reducing the need for urgent or eleaive rein- 
tervention, or both. 
Indications for Stenting 
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Tahte 2. Results of Rescue Stenting 
Stent and Implantation Early Myecardial Urgent In-Hapiral 
Skl& study hs success CIOWR Infaraicn CABG Death ReStefl0SF 
(ref no.) P&d (no.1 (a, (5) (2) (‘9 (5) (Tr) 
wausten: 
$wrt et al. (48) 1986-88 11 100 9 9 II 9 - 
de Feyter et al. (49) 1989-W 15 100 20 13.3 60’ 6.6 - 
Gay et al. (50) 1986-89 17 l&l 5.8 3.8 0 0 2s 
Eeckhout et al. (51) 1986-91 33 loo 24 30 9 3 9 
Giantwco&ubin 
Roubin et al. (19) 1989-91 115 96 7.6 6.7 4.2 1.7 - 
Heam et al. (52) 1987-90 116 R9 X.6 4 2.8’ 4 33 
Sutton et ai. (21) 1989-91 415 - - 5 12 3 - 
Chan et al. (53) 1991-94 42 95 24 5 7 0 - 
Palmaz-Schatz 
Haude et al. (54) - 15 Km 6.7 tl 6.1 0 21 
Hermann et al. (35) 1988-91 50 98 16 20 13 3.6 - 
Maiello et al. (56) 1990-92 32 loil 6 6 6 6 54 
Kiemeneij et al. (57) 1990-91 52 89 23 - 14’ 7 29 
Colombo et al. (58) 1989-92 56 100 ? 4 3 4 -36 
Foley et al. (59) lYYO-92 60 1cnl 16.7 21.6 7 0 SD 
Scbdmig et al. (60) 1989-93 327 96.3 6.9 4 9’ 1.3 29.6 
Alfonu, et al. (61) 1990-93 42 93 5 < 2.3 0 - 
wiitor 
Vmlii and Piesxns (62) 1990-91 69 95 17 - 3 3 
Strecker 
Reifan et al. (63) 1990-91 ‘la 97 21 2 6 10 - 
*Inchtdes patients in whom strnting was considered a bridge to operation. CABG = mroc;u) artery bypass grafting; Pts = patients: ref = reference. 
postprocedural regimen. Very low closure rates have been 
reported by Colombo et al. (11,12) using ultrasound guidance 
and high pressure angioplasty. 
Various other interventional strategies have been suggested 
for acute vessel closure during angioplasty (44). Although the 
results may seem promising, they were obtained in small series 
and in the hands of experienced operators. Repeat angioplasty 
and stenting remain the moSt commonly used and available 
techniques. Autoperfusion balloon angioplasty prolongs the 
intervention and has a nonnegligible failure rate that requires 
final crossover to stenting (44). In contrast to the many 
observational trials on bailout stenting, only two randomized 
trials have compared stenting (Palmaz-Schatz) with prolonged 
autoperfusion balloon angioplasty. The TA!X II trial (Trial of 
Angioplasty and Stems in Canada) (64), a small study of 43 
patients, found more clinical success (90% vs. 42%) and 
improved immediate angiographic results with stenting. The 
GRACE trial (Gianturco-Roubin stent Acute Closure Evalu- 
ation) (65), designed in 1992 and using the Gianturco-Rcubm 
stent, has not yet reported results. 
Akhough results of the GRACE trial are lacking, it may be 
concluded that stenting is a&ally the better technique for the 
management of acute or threatened closure during angio- 
plasty. A wide spectmm of conditions, from &optimal angio- 
graphic results after angioplasty to a large protruding dissee- 
tion with impaired dii flow or total vessel closure, may 
benefit from stent placement. Because large randomized trials 
are lacking, the operator sltoukl choose: the device with which 
he is most familiar and use high pressure angioplasty, depend- 
ing on the dent type (66). In cases of extreme vessel tortuosity 
or small vessel size. membrane-protected stems or the track- 
able Micro stent can be considered. Even the presence of 
thrombus in bailout situations does not seem to be a contra- 
indiition to stenting as Sutton et al. (21) found that it was not 
retained as a risk factor for adverse events in a multivariate 
analysis. Vety small vessel size (<U mm) is one of the last 
remaining absolute contraindications to stenting. However, 
patients with such vessels are also poor surgicd candidates and 
revascuk&ation should be carefuRy considered before percu- 
taneous intervention. Tii0pidine may be adminhtered before 
angioplasty in order to obtain thii drt@ full et&icy during the 
intervention. 
Re7§mo&afteraIsglapIaaty*primary~~ 
Four trials comparing stenting and angioplasty for new lesions 
in native cor0nary arteries have been conducted with the 
Pahnaz-Schatz stent; one smaller pilot study has been per- 
formed with the Wiior stent (9,1O,67-69). 
IntheRenestentI(n=52O)and!5TRESI(n=410)tria& 
patients with new discrete (length <IS mm) Iesions in large 
(Smm) native conmary arteries were rand0mii between 
1991 and 1993 in 4g centers in the IJ. S. and Europe. At 
6m0ntb follow-up (9,10x the essential cxmc%om were that 
elective implantatkm of an articulated Palmaz-Schatz stent 
inducedasustai&~bene6twithareduction0f 
tberestenosisrateby~~andlessneedforrepeatinterven- 
tion than that obtained with angioplasty. Further chnieal 
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‘Table 3. Results of Stenting for Restenotic Native Coronary Artety Lesions 
Stent and 
study 
(ref no.) 
Wallstent 
Sigwart et al. (72) 
Eeckhout et al. (51) 
Gianturco-Roubin 
Sutton et al. (21) 
Palmaz-Schatz 
Levine et al. (73) 
Schatz et al. (8) 
Colombo et al. (74) 
Savage et al. (75) 
Wiktor 
de Jaegere et al. (24) 
de Jaegere et al. (76) 
study 
Period 
i9%-? 
1986x6-91 
1989-91 
1988-89 
1987-89 
- 
1987-90 
MO-92 
MO-92 
PiS 
(no.) 
4-1 
59 
224 
37 
157 
97 
217 
50 
IO9 
Implantation Early Myoc-ardlat Urgent 
Succesb CIOSUW infarction CABG 
(51 (B) (%, V) 
loii i l - 2 
100 I2 5 3 
- - I 6 
95 3 - n 
94* 3.v 2.x* - 
9.5 2 1 I 
- 4.7’ 3.7 - 
98 IIJ 10 2 
- I? - 5 
D&h l&stenosis 
0) @) 
2 - 
2 17 
3 - 
0 2x 
0.S” - 
I 19 
0.7’ 39 
0 29 
I 30 
‘Includes small subgroups of patients with new lesions. Abbreviations as in Table 2. 
follow-up during 1 year in the Benestent I group (70) showed 
that these conclusions could be maintained. Despite these 
positive results, there were several problems. 1) The patients, 
to whom the preceding restrictive criteria apply, are only a 
small part of the general population of patients with coronary 
artery disease. 2) Patients who receiT:ed stents had received full 
anticoagulation, which caused a longer hospital stay and a 
higher incidence of bleeding problems with a need for surgical 
repair or blood transfusion (7.3% for STRESS I and 13.5% for 
Benestent I). 3) Only the Benestent I trial showed sustained 
clinical benefit with stenting. The STRESS I investigators 
reported a tendency toward benefit that prompted these 
investigators to proceed with further randomization (STRESS 
II). 
The START trial (STent versus Angioplasty Restenosis 
Trial) is a Spanish multicenter study that, like STRESS, 
included patients with unstable and multivessel disease (67). 
The study is about to lx completed and results, which are 
similar to those of the preceding trials, will soon be published. 
A fourth, smaller, study, the Canadian TASC I study, found a 
7% rate of myocardial infarction in patients with stents related 
to a historical problem of subacute closure (68). 
In contrast to the favorable results observed with the 
Palmaz-Schatz stent, primary Wiktor stenting of the right 
coronary artery did not show any clinical or angiographic 
advantage over standard angioplasty in a pilot study concem- 
ing 84 patients (69). At present, no further trials with this or 
other (than the Palmaz-Schatz) stents are planned. 
A pilot phase with 200 patients showed the safety (no case 
of stent thrombosis) of a new, heparin-coated Pahnaz-Schatz 
stent with a modified spiral articulation. This stent will be used 
in the Benestent II trial, which will investigate the efficacy of 
primary stenting in multivessel disease (71), evaluate major 
adverse clinical and angiographic events and perform a quality 
of lie analysii and a financial comparison. 
Seco&ry restenosis m Stent placement has been 
performed for the treatment of resten& lesions since 1986, 
and a limited number of observational studies with different 
stent types (Table 3) (8,24,21,72-76) have been published. 
Many of these series, which typically are not focused on 
secondary stenosis prevention, appear rather outdated. A 
nonnegligible incidence of subacute thrombosis and restenosis 
rates, varying between 17% and 39%, has been reported. 
Nevertheless, restenotic lesions have a different pathologic 
substrate from that of new stenotic lesions and may predispose 
to a higher incidence of a second restenosis. Savage et al. (75) 
reported a higher restenosis rate after stenting of restenotic 
versus new lesions. Thus, the favorable results of certain 
primary restenosis prevention trials cannot be extrapolated to 
secondary restenosis prevention and it is unclear whether 
stenting is superior to angioplasty for restenotic lesions. 
The REST trial (RIGstenosis STent study), initiated in 1991 
in Germany and currently extended to several European 
centers (77), investigates this issue in a randomized fashion. A 
first answer to this important topic is expected shortly. 
Saphenous vein graft stenting. Conventional angioplasty 
of vein graft lesions is limited by the risk of distal embolization 
of plaque during intervention and by a high incidence of 
restenosis (78). Fycept for stenting, new technology has been 
very disappointing and the only randomized trial (CAVEAT 
II, Coronary Andoplasty versus Excisional Atherectomy Trial) 
on vein graft lesions showed similar restenosis rates and a 
higher incidence oi periprocedural complications with direc- 
tional atherectomy in comparison with angioplasty (40). Stent- 
ing of such lesions has been performed since 1986, and the 
experience of several centers has been reported (Table 4) 
(79-90). Even before the era of ultrasound and high pressure 
angioplasty, stenting in vein graft lesions was characterized by 
very low subacute stent thrombosis rates whereas a 30% 
incidence rate of restenosis may be expected during follow-up. 
It is currentIy unclear whether stenting results in less distal 
embolization during intervention. This issue as well as the 
impact of stenting on restenosis will be addressed in the 
SAVED trial (Stent versus balloon Angioplasty for aorto- 
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Tabte 4. Results of Stenting in Saphenous Vein Graft Lesions 
Stem and 
study 
(ref no.) 
- 
Wallstent 
llrban et al. (79) 
de Qheerder et al. (X0) 
Strauss et al. (81) 
Eeekhout et al. (82) 
Palmaz-khatz 
Strttmpf et al. (83) 
Piana et al. (84) 
Maiello et al. (85) 
Wang et al. (86) 
Camma et al. (87) 
Fenton et al. (88) 
Wang et al. (89) 
Wiktor 
Fortuna et al. 190~ 
StUdy 
Period 
1986-88 
198x-90 
1986-90 
19%6-93 
199%91 
1988-93 
1990-93 
I99u-93 
198x-91 
1990-91 
- 
1991-93 
Ptr 
(no.) 
13 
69 
I.45 
40 
26 
I50 
43 
231 
84 
198 
589 
101 
Implantation 
SUCCCSS 
(%) 
100 
IX! 
1fW 
1Ml 
loo 
9n 
98 
‘Ix 
IMI 
99 
97 
1tXJ 
Edrly 
ClCWre 
(5) 
n 
10 
Y 
1 
4 
I 
s 
I 
0 
0.5 
I.4 
2 
Urgmt 
CABG 
P) 
u 
0 
- 
2 
0 
0 
L 
0.: 
It 
- 
0.9 
1 
Dmh Restmusis 
(5) iq) 
0 10 
I.5 47’ 
- .3-l 
II .35 
0 !3 
I 17 
II 
I.5 - 
II - 
3 
1.; Y.7 
1 - 
‘Includes patients with a XitJ% stenosis adjacent to the stentzd segment. Ahhwiations a in Table 2 
coronary saphenous Vein bypass graft Disease). the only 
randomized study on this subject comparing Pahnaz-Schatz 
stenting and angioplasty. Interim analysis (Yl) indicates that 
primary restenosis prevention tends to be as effective in vein 
grafts as in native coronary arteries. The Wallstent may be of 
particular interest for long lesions and for the prevention of 
distal embolization if used without predilation. Despite good 
immediate and mid-term in situ results, late restenosis (or 
renarrowing) may occur, and progression of coronary artery 
disease is common (82,&1,92). Therefore, late cardiac events 
are mostly inevitable and other measures, such as coronary risk 
factor correction, are essential in patients with vein graft 
lesions. 
Future areas for investigation of stenting. Aurtocoronary 
ostillesions. New technology (laser angioplasty, directional or 
rotational atherectomy and stenting) is effective for ostial 
stenoses (93). However, substantial data are lacking and 
suboptimal angioplasty results in ostial lesions should there- 
fore be treated by the technique with which the operator is 
most familiar. 
Chronic rofal o&&on. Again, limited experience with 
stenting has been gained in patients with this indication for 
stenting. Goldberg et al. (94) reported a second vessel closure 
in 5% and restenosis in 20% of their 59 patients. Medina et al. 
(95) descrii comparable results. One randomized trial 
(SPAmO) (Stents versus FKA After recanalization of 
Chronic Total coronary Occlusions) with the Wiktor stent is 
currently being undertaken. 
Acute mpcurdiui infamion. Stenting is currently being 
performed in patients with acute myocardial infarction who 
have s&optimal primary angioplasty’ results. Yet, large-scale 
data have not been published (96). The PAM1 (Primary 
Angioplasty for Myocardial Infarction) study group is consid- 
ering performing a controlled trial with the heparin-coated 
Pahnaz-Schatz stent in patients with acute myocardial infarc- 
tion. 
Cooclnsioos. intracoronary stents have improved the 
safety and efficacy of transcatheter cardiovascular therapy: 
They can reverse acute vessel or graft closure during coronary 
intervention, and certain devices have an “ant&stenosis” 
effect in selected patients. Most of these patients are also good 
surgical candidates, a group that excludes patients with distal 
lesions in very small vessels. 
Stents will not eliminate the restenosis problem. and a 
persistent restenosis rate of 10% to 15% should be expected 
with the best of current devices. However, it is a first step in 
restenosis prevention and may, in the future, be part of a more 
global approach to preventing restenosis that may also include 
stent irradiation and the use of local drug delivery or gene 
therapy with the use of polymeric or biodegradable stems as 
the vehicle for application. At present. hecause the learning 
curve is short and because coronq stent placement is the 
most efficient means of reversing acute vessel closure during 
angioplasty, the ability to use these devices is mandatory in 
every modem catheterization laboratory. 
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